ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    dndi | United Kingdom

Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03383614
Recruitment Status : Recruiting
First Posted : December 26, 2017
Last Update Posted : June 21, 2018
Sponsor:
Collaborators:
Bayer
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
Drugs for Neglected Diseases

Brief Summary:
The study evaluates safety, tolerability, PK and PD of emodepside, after administration as an Liquid Service Formulation (LSF), over 10 days, in healthy male Caucasian subjects.

Condition or disease Intervention/treatment Phase
Filariasis Drug: LSF emodepside (BAY 44-4400) oral solution (1mg/mL) Phase 1

Detailed Description:

There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O. volvulus adult worms, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in MDA programs. Emodepside is a promising candidate to kill the adult and sexually mature O. volvulus as explained below. Emodepside was shown to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).

A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of emodepside in healthy Caucasian men has been conducted and the preliminary results are favourable, support continuing the Phase I development program. In the present repeat dose study, pharmacokinetic as well as safety and tolerability of the liquid service formulation of emodepside, given over 10 days will be tested.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects
Actual Study Start Date : November 10, 2017
Estimated Primary Completion Date : October 1, 2018
Estimated Study Completion Date : October 1, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Emodepside

Arm Intervention/treatment
Experimental: cohort 1 (8 subjects)
6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
Drug: LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
LSF emodepside (BAY 44-4400) oral solution (1mg/mL) or matching placebo

Experimental: cohort 2 (8 subjects)
6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
Drug: LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
LSF emodepside (BAY 44-4400) oral solution (1mg/mL) or matching placebo

Experimental: cohort 3 (8 subjects)
6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
Drug: LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
LSF emodepside (BAY 44-4400) oral solution (1mg/mL) or matching placebo




Primary Outcome Measures :
  1. safety and tolerability of emodepside after multiple doses as measured by number of participants with treatment related adverse events [ Time Frame: up to 120 days ]
  2. safety and tolerability of emodepside after multiple doses as measured by number of participants with vital signs findings [ Time Frame: up to 120 days ]
  3. safety and tolerability of emodepside after multiple doses as measured by number of participants with 12-lead Electrocardiogram findings [ Time Frame: up to 120 days ]
  4. safety and tolerability of emodepside after multiple doses as measured by number of participants with clinical laboratory tests findings [ Time Frame: up to 120 days ]
  5. safety and tolerability of emodepside after multiple doses as measured by number of participants with ophthalmology assessments findings [ Time Frame: up to 120 days ]
  6. safety and tolerability of emodepside after multiple doses as measured by number of participants with physical examination findings [ Time Frame: up to 120 days ]
  7. safety and tolerability of emodepside after multiple doses as measured by number of participants with neurological examination findings [ Time Frame: up to 120 days ]

Secondary Outcome Measures :
  1. pharmacokinetics of emodepside at Day 0 and Day 9 (Cohorts 1 & 2: AUC24 and Cohort 3: AUC12) and at Day 9 : AUCinf [ Time Frame: at Day 0 and up to Day 9 ]
  2. pharmacokinetics of emodepside at Day 0 and Day 9 (Cmax) and at Day 9: AUCinf [ Time Frame: at Day 0 and up to Day 9 ]
  3. pharmacokinetics of emodepside: Ctrough will be derived from the concentration data (Days 1-9) [ Time Frame: at Day 1 and up to Day 9 ]
  4. time-matched profiles of selected pharmacodynamics (PD) markers in plasma after multiple doses of emodepside (Time-matched profiles of glucose, glucagon, insulin, and cortisol + Oral glucose tolerance test (OGTT) ) [ Time Frame: up to D30 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   only male subjects will be included
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male, Caucasian volunteers, deemed healthy based on a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
  2. 18 to 45 years of age.
  3. Normal body weight (BMI; Quetelet index) in the range 18 to 30.1 kg/m2 at screening.
  4. Blood pressure and heart rate in the supine position prior to randomisation must be within the ranges 90-140 mm Hg systolic, 60-90 mm Hg diastolic; heart rate 45-100 beats/min.
  5. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
  6. Willingness to give written consent to participate, after reading the information and consent form, and after having the opportunity to discuss the trial with the Investigator or his delegate.
  7. Willingness to agree to the contraceptive requirements of the study from the first dose until 120 days after the last dose of study medication
  8. Willingness to give written consent to have data entered into the Overvolunteering Prevention System

    Exclusion Criteria:

  9. Administration of a licensed or unlicensed medicinal product as part of another clinical trial within the 3 months before, or within 5 half-lives of, their first dose of study medication, whichever is longer, or is currently in the follow-up period for any clinical trial.
  10. Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness (such as diabetes mellitus or other abnormalities of glucose homeostasis) sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
  11. Past surgery (eg stomach bypass) or medical condition that might affect absorption of study drug taken orally.
  12. Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
  13. Loss of more than 400 mL of blood within 3 months before admission.
  14. Clinically relevant history of vital organ disease or other disease of an organ or the central nervous system.
  15. Current or previous medical or psychiatric disorder, condition or history of such (eg seizures) that, in the opinion of the Investigator or the Sponsor, would increase the risk associated with study participation, or impair the subject's ability to participate or complete this study.
  16. Positive test for hepatitis B, hepatitis C or HIV
  17. Febrile illness within 1 week before the first dose of study medication.
  18. History of severe allergy, non-allergic drug reactions, severe adverse reaction to any drug, or multiple drug allergies.
  19. Subjects with hypersensitivity to any ingredient of the study medication, including the active ingredient, emodepside.
  20. Presence or history of drug or alcohol abuse in the last 10 years, or intake of more than 21 units of alcohol weekly.
  21. Regular daily consumption of more than one liter of xanthine-containing beverages.
  22. Regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams (1/8 ounce) of tobacco.
  23. Use of a prescription medicine during the 28 days before the first dose of study medication or use of an over-the-counter medicine (with exception of acetaminophen (paracetamol)), during the 7 days before the first dose of study medication.
  24. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be inducers or inhibitors of CYP3A4, or other co-medications known to be relevant substrates of CYP3A4, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
  25. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be strong inhibitors of P-gp, or other co-medications known to be relevant substrates of P-gp, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
  26. Relevant pathological abnormalities in the ECG at screening, such as a second or third-degree AV block or prolongation of the QRS complex over 120 msec or QTc-interval over 450 msec (QTcB or QTcF).
  27. Evidence of drug abuse (via urine testing) at the screening assessment or admission to the ward
  28. Use of excluded therapies that may impact on the interpretation of study results in the opinion of the Investigator or Sponsor.
  29. Objection by General Practitioner (GP) to subject entering trial.
  30. History of residing for 6 or more continuous months, within the last 3 years, in regions with endemic parasitic infections as determined by the Investigator.
  31. Possibility that subject will not cooperate with the requirements of the protocol.
  32. No contact lenses wear within 1 month before dosing. Contact lenses wear is not permitted during the study.
  33. Any ocular disorder for which topical ocular therapy is currently or chronically prescribed, including inflammatory eye disease (dry eye allergic conjunctivitis [seasonal allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis], uveitis and glaucoma)
  34. Past history of ocular disease requiring ongoing treatment
  35. Past ocular surgery including laser or other refractive corneal surgery
  36. Evidence of eye irritation, visual difficulties, corneal opacity, ocular surface (corneal or conjunctival damage, with or without ocular symptoms)
  37. Evidence of narrow anterior chamber angles causing increased risk of acute glaucoma
  38. Evidence of ocular media opacity including lens opacity/vitreous opacities
  39. Evidence of retinal or optic nerve pathology
  40. Evidence of pronounced colour blindness, as indicated by an Ishihara score of 9/13 or below

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03383614


Contacts
Contact: Jean-Yves Gillon, PhD +41 22 906 92 30 jygillon@dndi.org
Contact: Sabine Specht, PhD +41 22 906 92 30 sspecht@dndi.org

Locations
United Kingdom
Hammersmith Medicines Research Limited Recruiting
London, United Kingdom, NW10 7EW
Contact: Jeremy Dennison, BSc MSc PhD MBChB    +44 20 89 63 45 46    jdennison@hmrlondon.com   
Contact: Frans van den Berg    +44 20 89 61 41 30    fvandenberg@hmrlondon.com   
Sponsors and Collaborators
Drugs for Neglected Diseases
Bayer
Bill and Melinda Gates Foundation
Investigators
Principal Investigator: Jeremy Dennison, BSc MSc PhD Hammersmith Medicines Research Limited

Responsible Party: Drugs for Neglected Diseases
ClinicalTrials.gov Identifier: NCT03383614     History of Changes
Other Study ID Numbers: DNDI-EMO-02
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Filariasis
Spirurida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases